Agentic AI for Small Pharma
Move from CRO-dependent execution to sponsor-controlled, AI-supervised delivery.
Small pharma sponsors operate under lean teams, runway pressure, and fixed milestone timelines.
Maxis AI deploys supervised AI execution capacity at the inflection points where complexity grows fastest — preserving runway and avoiding internal team expansion.
Human-in-the-loop validation · Audit traceability
Our platform strengthens execution across critical workflows.
Study Startup Support
- Faster startup readiness
- Improved activation tracking
Clinical Data Management
- Automated data cleaning
- Faster database readiness
Statistical Programming Support
- Automated dataset preparation
- Improved biometrics efficiency
Operational Oversight
- Continuous monitoring across trials
- Earlier risk detection
Where Small Pharma Execution Slows
Execution challenges commonly occur due to:
Limited internal operational capacity
Heavy dependence on CRO delivery
Delays in biometrics workflows
Limited real-time execution visibility
Small teams managing complex workflows
What Improves with Agentic AI
With agentic AI for small pharma, execution becomes more scalable.
Faster database readiness timelines
Reduced dependency on manual workflows
Earlier risk detection
Improved operational visibility
Stronger execution predictability
Recommended Approach
Deploy supervised execution capacity at the Phase 1 to Phase 2 transition — when complexity increases but teams remain lean. Organizations that do this advance to database lock 40–50% faster while preserving runway and avoiding internal team expansion.
Phase 2 Delivered. No Biometrics Build. DB Lock in 3–4 Months.
See how a Series B oncology biotech scaled Phase 2 biometrics execution without a 12–18 month build or full-service CRO dependency.
3–4 Months
DB lock vs 8–10 projected
4–6 Months
Submission accelerated
60–70%
Queries auto-resolved
0
Permanent hires required
All You Need to Know
It expands execution capacity without increasing headcount.
Yes. It improves internal execution capability.
Supervised execution enables lean teams to scale Phase 1 trial capacity, reducing cost and timeline variability without expanding internal headcount.
Yes. It supports Phase I, II, and III execution.
Yes. It enables enterprise-level execution capacity.
Explore the Agentic AI Platform.
See how AI agents are transforming study startup, data management, oversight, and regulatory submissions.